ESTIMATION OF TRACE LEVEL OF N-NITROSO FLUOXETINE IMPURITY IN FLUOXETINE CAPSULES BY LC-MS/MS

Authors

DOI:

https://doi.org/10.22159/ijap.2026v18i1.56278

Keywords:

Nitrosamine, NDSRINDSRI, Fluoxetine capsules, N-Nitroso fluoxetine, Liquid chromatography, Mass spectrometry, Multiple ion reaction monitoring

Abstract

Objective: Nitrosamine impurities, particularly nitrosamine drug substance related impurities (NDSRIs), have gained focus in recent past due to their carcinogenic potential. Due to the low sensitivity of conventional techniques like; high performance liquid chromatography (HPLC) and gas chromatography (GC), the exact levels of these impurities could not be determined. This study aims to develop and validate a sensitive liquid chromatography hyphenated with mass spectrometry (LC-MS/MS) method to estimate the trace levels of N-Nitroso fluoxetine (a fluoxetine-related NDSRI) in fluoxetine capsules (60 mg).

Methods: We developed a sensitive and selective LC-MS/MS method for the quantification of trace levels of N-Nitroso fluoxetine in fluoxetine capsules (60 mg) using the AB Sciex 5500+ quadrupole ion trap (QTRAP) LC-MS/MS system. To achieve the maximum response at quantitation level for N-Nitroso fluoxetine impurity, chromatographic conditions optimized by selecting a specific combination of column, mobile phase, and diluent. Mobile Phase A and B consisted of 10 mM ammonium acetate buffer and methanol respectively. Waters X-Bridge C18 column (250 × 4.6 mm, 3.5 μm, Part No. 186003943) at temperature 40°C and mobile phase flow rate to 0.5 mL/min has yielded consistent results by employing an optimized gradient elution program (Tmin/%B): 0/75, 2/75, 16/95, 28/98, 28.1/75, and 35/75 for the analysis. To further maximize the response of the N-Nitroso fluoxetine impurity, the multiple ion reaction monitoring (MRM) mass spectrometry method in positive electron spray ionization (ESI) mode is preferred over single ion monitoring (SIM) method. 

Results: The newly developed method is validated by performing parameters such as specificity, method precision, intermediate precision, detection limit, quantitation limit, linearity, and accuracy in accordance with the international conference on harmonization (ICH Q2 (R1)) Guidelines. Limit of detection (LOD) and limit of quantitation (LOQ) are established as 0.06 ppm and 0.11 ppm, respectively. The method is found capable to demonstrate accuracy, precision, and linearity across the range of 0.11 to 1.68 ppm (10% to 150% of the specification), where linearity study shows the correlation coefficient (r²) greater than 0.99 for linearity plot between concentration and area. Recovery data at 10%, 50%, 100%, and 150% of the specification levels indicates that the recovered impurity content observed between 80% and 120%. Based on these results, we have successfully established the method for batch analysis of fluoxetine capsules (60 mg).

Conclusion: A new rapid and sensitive reverse-phase ultra-high-performance liquid chromatographic (UHPLC) method coupled with a mass spectrometry detector has been developed and validated for the estimation of N-Nitroso fluoxetine impurity in fluoxetine capsules. Method validation is accomplished according to the ICH Q2 (R1) guidelines, assessing parameters such as limit of detection, limit of quantitation, accuracy, precision, and linearity. We found the method suitable for its intended use and successfully applied it to test batches of the fluoxetine capsules drug product.

References

1. Mikocka-Walus A, Prady SL, Pollok J, Esterman AJ, Gordon AL, Knowles S, Andrews JM. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database Syst Rev. 2019 Apr 12; 2019(4):CD012680.doi: 10.1002/14651858.CD012680.pub2, PMID: 30977111.

2. Dhenain T, Côté F, Coman T. Serotonin and orthodontic tooth movement. Biochimie. 2019 Jun; 161:73-79.

3. Burch R. Antidepressants for Preventive Treatment of Migraine. Curr Treat Options Neurol. 2019 Mar 21; 21(4):18.

4. Guideline IH. Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH): Geneva; 2014. doi: 10.1002/9781119551249.ch2.

5. US Food and Drug Administration. FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan). Silver Spring, (MD): United States Food and Drug Administration; 2019. doi: 10.1002/9781119551249.

6. European Medicines Agency. Update on review of valsartan medicines following detection of impurity in active substance, EMA/485921/2018. London: European Medicines Agency; 2018.

7. European Medicines Agency. EMA review of impurities in sartan medicines. EMA/643116/2018. London: European Medicines Agency; 2018.

8. US Food and Drug Administration. Control of nitrosamine impurities in human drugs: guidance for industry. Pharmaceutical Quality/Manufacturing Standards (CGMP), Revision 2, September 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits

9. Ashworth I W, Dirat O. Teasdale A. Whiting M P, Potential for the Formation of N-Nitrosamines during the Manufacture of Active Pharmaceutical Ingredients: An Assessment of the Risk Posed by Trace Nitrite in Water. Org. Process Res. Dev. 2020, 24 (9), 1629– 1646, DOI: 10.1021/acs.oprd.0c00224

10. Mirvish SS. Formation of N-nitroso compounds: chemistry, kinetics, and in vivo occurrence. Toxicol Appl Pharmacol. 1975; 31(3):325-51. doi: 10.1016/0041-008X(75)90255-0, PMID 238307.

11. Schlingemann J, Burns M J, Ponting D J, Avila C M, Romero N E, Jaywant M A, Smith G F, Ashworth I W, Simon S, Saal C, Wilk A, The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals. J. Pharm. Sci. 2023, 112, 1287, doi: 10.1016/j.xphs.2022.11.013.

12. Kruhlak NL et al. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA). Regul Toxicol Pharmacol. 2024 Jun; 150:105640.

13. Ponting DJ, Czich A, Felter SP, Glowienke S, Harvey JS, Nudelman R, Schlingemann J, Simon S, Smith GF, Teasdale A, Thomas R. Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakes. Regul Toxicol Pharmacol. 2025 Feb; 156:105762

14. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits#compound

15. Sohel A J, Shutter M C, Patel P, Molla M. fluoxetine, University of California, Los Angeles, StatPearls Publishing; 2025 Jan. PMID: 29083803. Bookshelf ID: NBK459223

16. Boetzel R, Schlingemann J, Hickert S, Korn C, Kocks G. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products. J Pharm Sci. 2023 Jun; 112(6):1615-1624. doi:10.1016/j.xphs.2022.04.016, PMID: 35500671

17. Bruins AP. Mechanistic aspects of electrospray ionization. J Chromatogr A 1998; 794: 345-57.

18. Patidar A, Kamble P. A Comprehensive Review on Liquid Chromatography-Mass Spectrometry (LC-MS): A Hyphenated Technique: A Review, Asian Journal of Pharmaceutical Research and Development. 2025; 13(1):95-103. doi: 10.22270/ajprd.v13i1.1509

19. Famiglini G, Palma P, Termopoli V, Cappiello A. The history of electron ionization in LC-MS, from the early days to modern technologies: A review. Analytica Chimica Acta. 1167 (2021) 338350.doi: 10.1016/j.aca.2021.338350

20. LC-MS/MS analytical procedure for the determination of N-Nitroso-fluoxetine in fluoxetine tablets. European Directorate for the Quality of Medicines & Healthcare (EDQM) (https://www.edqm.eu/en/d/1925195).

21. Bhavyasri K, Saileela S, Sumakanth M. High-Resolution Mass Spectroscopy (HRMS)-A Review, Int J Curr Pharm Res, Vol 15, Issue 3, May-June, 2023, 9-13, doi, 10.22159/ijcpr.2023v15i3.3008.

22. ICH; Harmonised tripartite guideline validation of analytical procedures: text and methodology Q2 (R1). In International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, (2005), pp. 1–13.

23. Remidicherla SS, Chakravarthi G, Malothu N. A validated LC-MS/MS method for determination at trace level of nitrosamine impurities in doxofylline API. Indian J Pharm Educ Res.2024; 58(4s):s1262-70. doi: 10.5530/ijper.58.4s.121.

24. Baksam VK, Saritha N, Devineni SR, Jain M, Kumar P, Shandilya S. A critical n-nitrosamine impurity of anticoagulant drug, rivaroxaban: synthesis, characterization, development of LC–MS/MS method for nanogram level quantification. Chromatographia. 2022; 85(1):73-82. doi: 10.1007/s10337-021-04115-x.

Published

11-11-2025

How to Cite

KUMAR, B., MUDHULKAR, R., VENUGOPALA RAO, D., & LODHI, S. S. (2025). ESTIMATION OF TRACE LEVEL OF N-NITROSO FLUOXETINE IMPURITY IN FLUOXETINE CAPSULES BY LC-MS/MS. International Journal of Applied Pharmaceutics, 18(1). https://doi.org/10.22159/ijap.2026v18i1.56278

Issue

Section

Original Article(s)

Similar Articles

<< < 1 2 3 4 5 > >> 

You may also start an advanced similarity search for this article.